Certara, Inc. has announced its financial results for the third quarter of 2026, revealing a strong performance driven by double-digit growth in software revenue. The company also appointed Grant Peterson as its new Chief Product Officer, indicating a strategic focus on enhancing its product offerings. This development is significant as it highlights Certara's commitment to innovation in a competitive industry.
Based in Radnor, Pennsylvania, Certara, Inc. operates in the prepackaged software sector, specifically under the SIC code 7372. The company is publicly traded on the Nasdaq under the ticker symbol CERT. Certara has consistently focused on model-informed drug development, providing software solutions to improve the efficiency of drug development processes.
According to the recent SEC filing dated November 5, 2026, Certara reported a revenue of $94.9 million for the third quarter, up from $90.9 million in the same period last year, marking a growth of 4%. Notably, software revenue reached $48.8 million, reflecting an 11% increase compared to the previous year. The company also reported a net loss from continuing operations of $3.6 million, an improvement from the $4.8 million loss reported in Q3 2025.
The financial results indicate a positive trend for Certara, particularly in software revenue, which has been a focal point for the company. The appointment of Grant Peterson as Chief Product Officer is expected to further enhance the company's product strategy and growth trajectory. Peterson brings over 25 years of experience in technology and enterprise software, having previously served as Chief Product Officer at Conga and Chief Technology Officer at DocuSign.
This update is likely to impact various stakeholders, including investors, employees, and customers, as Certara continues to refine its operational strategies and product offerings. The emphasis on software growth aligns with broader trends in the prepackaged software industry, where companies are increasingly focusing on innovation and customer-centric approaches to drive revenue.
Looking ahead, Certara has narrowed its full-year revenue growth outlook to a range of 2% to 3%. The company will continue to monitor its performance and adjust its strategies as necessary. Further details on the company's financial health and strategic direction are expected in upcoming filings and conference calls.
Read Next
Advanced Flower Capital reports Q3 2026 financial results
Envoy Medical Reports Third Quarter 2026 Financial Results
Twin Vee PowerCats Reports Q3 Results, Highlights Growth
Collegium Pharmaceutical Reports Strong Q3 Results
Cronos Group reports Q3 2026 results, highlights growth focus
Lucky Strike Entertainment Corp Reports Strong Q3 Results



